APOE and Alzheimer disease: Reductions in the morphometry of these networks are typically observed in groups of individuals with an AD diagnosis, in at-risk individuals’ such as those with mild cognitive impairment (MCI) or those with increased genetic risk, via possession of APOE ε4 or a higher AD polygenic score (AD-PRS) [5].